Taysha Gene Therapies, Inc. (TSHA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 6M 12M 18M Q4 '23: 15.5M Q1 '24: 14.2M Q2 '24: 12.9M Q3 '24: 9.9M Q4 '24: 8.3M Q1 '25: 7.2M Q2 '25: 8.1M Q3 '25: 6.3M Q4 '25: 9.8M Q1 '26: 7.5M Q2 '26: 5.5M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-210M -140M -70M 0 70M 140M 210M Q4 '20: -43M Q1 '21: -69.5M Q2 '21: -106.3M Q3 '21: -141.9M Q4 '21: -173.3M Q1 '22: -190.8M Q2 '22: -183.4M Q3 '22: -158.2M Q4 '22: -162.4M Q1 '23: -129.4M Q2 '23: -119.4M Q3 '23: -110.2M Q4 '23: -72.4M Q1 '24: -80.2M Q2 '24: -78.1M Q3 '24: -87.8M Q4 '24: -91.5M Q1 '25: -88.5M Q2 '25: -94M Q3 '25: -102.1M Q4 '25: -110.5M Q1 '26: -132.6M Q2 '26: -153.2M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-240M -160M -80M 0 80M 160M 240M Q3 '20: -42.8M Q4 '20: -60M Q1 '21: -86.6M Q2 '21: -106.3M Q3 '21: -142.5M Q4 '21: -174.5M Q1 '22: -192.8M Q2 '22: -186M Q3 '22: -161.3M Q4 '22: -166M Q1 '23: -133.3M Q2 '23: -123.8M Q3 '23: -214.4M Q4 '23: -111.6M Q1 '24: -118M Q2 '24: -114.3M Q3 '24: -22.8M Q4 '24: -89.3M Q1 '25: -86.8M Q2 '25: -92.7M Q3 '25: -99.9M Q4 '25: -109M Q1 '26: -129.9M Q2 '26: -149.6M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q3 '20: -10.9M Q4 '20: -30.7M Q1 '21: -51.1M Q2 '21: -71.4M Q3 '21: -96.6M Q4 '21: -117M Q1 '22: -135.9M Q2 '22: -146.5M Q3 '22: -143.4M Q4 '22: -88.4M Q1 '23: -67.6M Q2 '23: -53M Q3 '23: -42.2M Q4 '23: -73M Q1 '24: -72.6M Q2 '24: -75.4M Q3 '24: -79M Q4 '24: -81.2M Q1 '25: -83.4M Q2 '25: -82.1M Q3 '25: -84.7M Q4 '25: -93.1M Q1 '26: -111.9M Q2 '26: -132.2M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q3 '21: -103.7M Q4 '21: -132.3M Q1 '22: -159.1M Q2 '22: -174.5M Q3 '22: -169.9M Q4 '22: -109M Q1 '23: -83.7M Q2 '23: -61.2M Q3 '23: -48.4M Q4 '23: -76.9M Q1 '24: -72.7M Q2 '24: -75.7M Q3 '24: -79.4M Q4 '24: -81.6M Q1 '25: -84.1M Q2 '25: -82.5M Q3 '25: -85.2M Q4 '25: -93.8M Q1 '26: -112.3M Q2 '26: -132.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q2 '21: 37.5M Q3 '21: 38M Q1 '22: 38.2M Q2 '22: 40.1M Q3 '22: 40.9M Q1 '23: 63.3M Q2 '23: 64.2M Q3 '23: 125.7M Q1 '24: 231.2M Q2 '24: 232.8M Q3 '24: 267.8M Q1 '25: 269.3M Q2 '25: 298M Q3 '25: 353.3M Q1 '26: 366.6M Q2 '26: 369M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q4 '20: -3.40 Q1 '21: -3.77 Q2 '21: -2.91 Q3 '21: -2.98 Q4 '21: -4.64 Q1 '22: -5.09 Q2 '22: -4.85 Q3 '22: -4.15 Q4 '22: -3.81 Q1 '23: -2.77 Q2 '23: -2.30 Q3 '23: -2.58 Q4 '23: -0.96 Q1 '24: -0.78 Q2 '24: -0.49 Q3 '24: 0.34 Q4 '24: -0.36 Q1 '25: -0.34 Q2 '25: -0.34 Q3 '25: -0.33 Q4 '25: -0.34 Q1 '26: -0.38 Q2 '26: -0.42 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.